A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, placebo-controlled, multi-center study will evaluate the
safety and the effect of RO5093151 on intraocular pressure in patients with ocular
hypertension or open angle glaucoma. Patients will be randomized to receive oral doses of
RO5093151 or placebo twice daily. The anticipated time on study treatment is 7 days with the
possibility to extend to 28 days.